Old Web
English
Sign In
Acemap
>
Paper
>
11 Second-line erlotinib in unselected NSCLC: audit of benefit
11 Second-line erlotinib in unselected NSCLC: audit of benefit
2011
Gordon Urquhart
E. Semple
E Steven
Keith M. Kerr
Marianne Nicolson
Keywords:
Erlotinib
Audit
Medicine
Internal medicine
Oncology
second line
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]